PAR — Paradigm Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- AU$120.72m
- AU$96.13m
- AU$6.52m
- 54
- 18
- 84
- 54
Annual income statement for Paradigm Biopharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | C2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.65 | 8.58 | 7.89 | 8.49 | 6.52 |
| Cost of Revenue | |||||
| Gross Profit | — | 8.48 | 7.75 | 8.47 | 6.51 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 16.9 | 43.2 | 48 | 60 | 65.1 |
| Operating Profit | -12.3 | -34.6 | -40.1 | -51.5 | -58.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -12.3 | -34.3 | -39.2 | -51.9 | -58.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -12.3 | -34.3 | -39.2 | -51.9 | -58.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -12.3 | -34.3 | -39.2 | -51.9 | -58.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.3 | -34.3 | -39.2 | -51.9 | -58.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.059 | -0.162 | -0.163 | -0.18 | -0.167 |
| Dividends per Share |